Related references
Note: Only part of the references are listed.Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Rosario Mazzola et al.
RADIATION ONCOLOGY (2020)
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
Relinde I. Y. Lieverse et al.
MOLECULAR ONCOLOGY (2020)
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
Brendan Curti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I. Y. Lieverse et al.
BMC CANCER (2020)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
Joshua M. Bauml et al.
JAMA ONCOLOGY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
David A. Palma et al.
BMC CANCER (2019)
Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy
Prashant Gabani et al.
RADIOTHERAPY AND ONCOLOGY (2018)
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Nicolle H. Rekers et al.
ONCOIMMUNOLOGY (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Combining radiotherapy with immunotherapy: the past, the present and the future
Evert J. Van Limbergen et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
Radiation induced liver disease: A clinical update
R. Benson et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2016)
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
Michel M. van den Heuvel et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
Nicolle H. Rekers et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
Nicolle H. Rekers et al.
ONCOIMMUNOLOGY (2015)
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M. L. Zegers et al.
CLINICAL CANCER RESEARCH (2015)
Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy
Kimberly S. Corbin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Stereotactic body radiotherapy for multisite extracranial oligometastases Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
Joseph K. Salama et al.
CANCER (2012)
Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis
Jose Luis Lopez Guerra et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study
Michael T. Milano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer
Michael D. Hasselle et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Thomas K. Eigentler et al.
CLINICAL CANCER RESEARCH (2011)
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
Manfred Johannsen et al.
EUROPEAN JOURNAL OF CANCER (2010)
Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
Michael T. Milano et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions
Michael T. Milano et al.
CANCER (2008)
DESCRIPTIVE ANALYSIS OF OLIGOMETASTATIC LESIONS TREATED WITH CURATIVE-INTENT STEREOTACTIC BODY RADIOTHERAPY
Michael T. Milano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
B Carnemolla et al.
BLOOD (2002)
Share Paper
